indium In 111 ibritumomab tiuxetan
Sponsors
University of Alabama at Birmingham, National Cancer Institute (NCI), Memorial Sloan Kettering Cancer Center, City of Hope Medical Center
Conditions
AIDS-related Peripheral/Systemic LymphomaAIDS-related Primary CNS LymphomaContiguous Stage II Adult Diffuse Large Cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueGraft Versus Host DiseaseLeukemiaLymphomaNodal Marginal Zone B-cell Lymphoma
Phase 1
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
TerminatedNCT00012298
Start: 2001-04-30End: 2010-04-30Updated: 2018-08-09
Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma
TerminatedNCT00036855
Start: 2002-06-30Updated: 2013-01-17
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder
CompletedNCT00064246
Start: 2003-07-31Updated: 2013-01-25
Phase 2
Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
CompletedNCT00058422
Start: 2003-02-10End: 2019-11-14Updated: 2020-11-12
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
CompletedNCT00005592
Start: 1999-11-30End: 2005-11-30Updated: 2015-10-21
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
TerminatedNCT00088881
Start: 2004-12-31End: 2011-03-31Updated: 2017-05-25
A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan
CompletedNCT00577278
Start: 2007-10-03End: 2023-12-14Updated: 2024-02-16